These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 15241818)

  • 1. Novel therapies for myelodysplastic syndromes.
    Faderl S; Kantarjian HM
    Cancer; 2004 Jul; 101(2):226-41. PubMed ID: 15241818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New agents in myelodysplastic syndromes.
    Jabbour EJ; Giles FJ
    Curr Hematol Rep; 2005 May; 4(3):191-9. PubMed ID: 15865871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel agents for the management of myelodysplastic syndromes.
    Meletis J; Viniou N; Terpos E
    Med Sci Monit; 2006 Sep; 12(9):RA194-206. PubMed ID: 16940944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating myelodysplastic syndromes.
    Ryan C; McCann S
    IDrugs; 2005 Apr; 8(4):320-6. PubMed ID: 15800807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug insight: emerging new drugs in the treatment of myelodysplastic syndromes.
    Faderl S; Kantarjian HM
    Nat Clin Pract Oncol; 2005 Jul; 2(7):348-55. PubMed ID: 16075794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Myelodysplastic syndromes].
    Paladini G; Pecorari P; De Sabbata G; Sammartini C
    Recenti Prog Med; 2004 Feb; 95(2):108-19. PubMed ID: 15072397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incorporating novel agents in the treatment of myelodysplastic syndromes.
    Anargyrou K; Vassilakopoulos TP; Angelopoulou MK; Terpos E
    Leuk Res; 2010 Jan; 34(1):6-17. PubMed ID: 19656566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Refractory anemia and the myelodysplastic syndromes.
    Lawrence LW
    Clin Lab Sci; 2004; 17(3):178-86. PubMed ID: 15314893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pediatric myelodysplastic syndromes.
    Rytting ME
    Curr Hematol Rep; 2004 May; 3(3):173-7. PubMed ID: 15087064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nucleoside analogs and antimetabolite therapies for myelodysplastic syndrome.
    Foss FM
    Best Pract Res Clin Haematol; 2004 Dec; 17(4):573-84. PubMed ID: 15494295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of patients with higher risk myelodysplastic syndromes.
    Fukumoto JS; Greenberg PL
    Crit Rev Oncol Hematol; 2005 Nov; 56(2):179-92. PubMed ID: 15979321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative review of classification systems in myelodysplastic syndromes (MDS).
    Bennett JM
    Semin Oncol; 2005 Aug; 32(4 Suppl 5):S3-10. PubMed ID: 16085011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical implications of the World Health Organization's classification of myelodysplastic syndromes.
    Komrokji RS; Bennett JM
    Curr Hematol Rep; 2005 May; 4(3):175-81. PubMed ID: 15865868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging drugs for the treatment of myelodysplastic syndrome.
    Nivatpumin PJ; Gore SD
    Expert Opin Emerg Drugs; 2005 Aug; 10(3):569-90. PubMed ID: 16083330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study.
    Vey N; Bosly A; Guerci A; Feremans W; Dombret H; Dreyfus F; Bowen D; Burnett A; Dennis M; Ribrag V; Casadevall N; Legros L; Fenaux P
    J Clin Oncol; 2006 Jun; 24(16):2465-71. PubMed ID: 16651646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review.
    Oliansky DM; Antin JH; Bennett JM; Deeg HJ; Engelhardt C; Heptinstall KV; de Lima M; Gore SD; Potts RG; Silverman LR; Jones RB; McCarthy PL; Hahn T
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):137-72. PubMed ID: 19167676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytogenetic aspects of adult primary myelodysplastic syndromes: clinical implications.
    Panani AD; Roussos C
    Cancer Lett; 2006 Apr; 235(2):177-90. PubMed ID: 15935553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The evolution of hematopoietic SCT in myelodysplastic syndrome.
    Kindwall-Keller T; Isola LM
    Bone Marrow Transplant; 2009 Apr; 43(8):597-609. PubMed ID: 19252532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes.
    Schiller GJ; Slack J; Hainsworth JD; Mason J; Saleh M; Rizzieri D; Douer D; List AF
    J Clin Oncol; 2006 Jun; 24(16):2456-64. PubMed ID: 16651647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on the therapy for myelodysplastic syndrome.
    Kasner MT; Luger SM
    Am J Hematol; 2009 Mar; 84(3):177-86. PubMed ID: 19195035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.